Hypofractionated stereotactic radiotherapy and radiosurgery for the treatment of patients with radioresistant brain metastases.
Marta Scorsetti(Humanitas University), Michele Del Vecchio(Fondazione IRCCS Istituto Nazionale dei Tumori), Gaetano Urso(Fondazione Humanitas per la Ricerca), P. Lattuada(Fondazione Humanitas per la Ricerca), Angelica Facoetti(University of Pavia), Pietro Mancosu(Fondazione Humanitas per la Ricerca), Mario Bignardi(Fondazione Humanitas per la Ricerca), S. Vigorito(European Institute of Oncology), Michela De Santis(Fondazione Humanitas per la Ricerca), Piera Navarria(Fondazione Humanitas per la Ricerca), Stefania Agostino Ninone(Fondazione Humanitas per la Ricerca)
PubMed
October 1, 2009
Cited by 27
Related Papers
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k
Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation
|The Lancet Oncology|2020|1.1k
Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial
|The Lancet Oncology|2017|780
Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document
|Radiotherapy and Oncology|2020|646
Interleukin-12: Biological Properties and Clinical Application
|Clinical Cancer Research|2007|606